Osimertinib-Related QTc Prolongation: Real-World Incidence and Impact of Drug Dosing on Recurrence Risk.

No abstract is available for this paper.

• Publication year

  2024

• Venue

  Clinical Lung Cancer

• Publication date

  2024-07-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.cllc.2024.06.012PMID 39069437
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma.

  2021cited by this paper
• Osimertinib-Induced Cardiotoxicity

  2019cited by this paper
• Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.

  2019cited by this paper
• Prevalence and risk factors of prolonged corrected QT interval in general Chinese population

  2019cited by this paper
• Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

  2017cited by this paper
• Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.

  2016cited by this paper
• Institution-wide QT alert system identifies patients with a high risk of mortality.

  2013cited by this paper
• The Long QT Syndrome: Prospective Longitudinal Study of 328 Families

  1991cited by this paper

• Fluoxetine/osimertinib/verapamil

  2025cites this paper